Entheon Biomedical Corp (CSE:ENBI) (OTCMKTS:ENTBF) CEO Timothy Ko tells Proactive the Vancouver, British Columbia-based group will look to begin clinical studies using DMT by late 2021.
Ko will be presenting at KCSA Strategic Communications' psychedelic-focused investor conference January 26th and 27th.